Oriola Oyj (ORIOLA) Earnings Call Transcript & Summary

October 29, 2026

Nasdaq Helsinki FI Health Care Health Care Providers and Services earnings 38 min

Earnings Call Speaker Segments

Tua Stenius-Ornhjelm

executive
#1

Good morning, and a warm welcome to the audiocast on Oriola's third quarter results. I'm Tua Stenius-Ornhjelm, from Investor Relations at Oriola. With me today are our CEO, Katarina Gabrielson, and our CFO, Mats Danielsson. Katarina will begin by taking us through the quarter, and then Mats will go over the financials. After that, we'll open up the Q&A. As a reminder, we'll first focus on questions relating to Oriola's business and financial performance. Feel free to submit questions through the chat at any point during the presentation. And just a practical note, today's audiocast is being recorded, and the recording will be available on our website later today. Before we get started, a quick look at our customary disclaimer. And with that, Katarina, over to you.

Katarina Gabrielson

executive
#2

Thank you, Tua, and a warm welcome from me as well. Looking at the third quarter, our business delivered a solid performance, and we kept reinforcing profitable growth. Later in this presentation I'll return to how we achieved that. In particular, commercial execution, operational improvements, and infrastructure development were the areas that kept bolstering the performance. Net sales rose by 5%, backed by sustained high volumes in specialty flows, sales growth in wholesale, and also strong sales in special-licensed medicines. In the last quarter, we discussed at length higher fuel prices and how we might pass costs through to our customers. That is something we succeeded with in the third quarter, and I'm genuinely pleased to see it has worked. However, during the quarter we also recorded a one-off inventory provision, and you'll hear more about it as this presentation continues. It amounted to EUR 0.7 million and it weighed on group profitability, so we ended up at last year's level. During the quarter, we also had stable supply chain operations. We hold a lot of volumes in our warehouses, and to some extent that depends on the geopolitical situation surrounding us.

Katarina Gabrielson

executive
#3

So that means we're dealing with elevated inventory levels as well as capacity constraints. In the quarter, we also announced a revisit of our implementation strategy for the ERP and warehouse management program. That's been updated drawing on lessons from the first deployment we carried out in Sweden at the end of last year. The timeline now permits us to do parallel core build and also direct deployment into Jarvenpaa. We'll return to that a bit later in this presentation as well. One highlight from this quarter is, of course, Kronans Apotek. We saw yet another quarter of growth and profitability improvements from Kronans Apotek. It's mainly been driven by a disciplined focus on commercial performance and cost efficiency. And this is also then grounded in the CMD discussions we held earlier this year. And I know Mats will come back to the Kronans Apotek figures later on. But moving on now to the operating environment. At Oriola, we saw stable market shares in Finland and Sweden during the quarter. Pharmaceutical distribution in Sweden was around 8%, while growth in Finland stayed low at only 0.5%. The geopolitical development I mentioned earlier, particularly regarding fuel prices and inflationary pressures, is still present, and it contributes, of course, to an uncertain operating environment going forward as well.

Katarina Gabrielson

executive
#4

We can observe that pharma firms are to some degree accumulating stock on this basis, since that ties to how you subsequently secure availability of pharmaceuticals across our markets. Within Advisory Services, geopolitical developments keep producing more guarded decision-making among customers, as we noted earlier in the year as well. That translates into extended lead times on new engagements. During the third quarter, consumer confidence in Finland and Sweden has differed somewhat between the two countries. In Finland, we see it sitting under the long-term average, whereas in Sweden by the close of the quarter it has climbed steeply and now matches the historical average. Moving then to the Services segment, I'll begin with Services, which comprises pharmaceutical distribution, value-adding services and parallel import across the Nordics. This segment also includes Advisory Services and Commercial Data Solutions. Net sales for the Services segment grew 3.7% and came in at EUR 36.4 million, with support coming particularly from volumes in the specialty flows -- specialty flows here covers the export business, vaccines and animal health as well.

Katarina Gabrielson

executive
#5

We’re also seeing strong progress in direct-to-pharmacy deliveries. Adjusted EBITDA came in better, at EUR 10.1 million. That improvement in adjusted EBITDA was largely fueled by the net sales growth I referred to earlier. If you recall what we discussed at the CMD, we spent considerable time in this segment on the strength of the joint — the customer and joint account planning. And that’s an area where we can see we’ve put in substantial effort over the quarter and across the full year as well. That’s now showing up too when we look at expanded key partnerships and a healthy pipeline throughout the markets. We now have new key partnerships that will impact both quarter 4 and the business starting in 2027. In Advisory Services, sales stayed soft in the quarter, essentially because pharmaceutical companies are taking longer to make decisions. What we’ve focused on in the advisory business is strengthening customer engagement further and doing more work on integrated businesses, including across all the countries where we provide advisory services.

Katarina Gabrielson

executive
#6

Over in Sweden, we rolled out a commercial data service powered by AI. Pharmaceutical companies have also purchased that offering, and it covers the medical information we hold, taking the data within our medical information and converting it into actionable product insights that now assist those pharma companies when making decisions. Then let's move on to the Products segment. This segment is made up of wholesale of traded goods and over-the-counter products, and it also covers our own brands plus the specialized medicines we have in Finland and Sweden. Included in the segment as well is the dose dispensing business we operate in Finland. Net sales for this segment grew 8.8% and came in at EUR 16.8 million, with growth in wholesale overall being a particular driver, along with strong sales of special-licensed medicines, as well as the dose dispensing business in Finland. I'm also glad to note that we've now begun selling to one new customer in Sweden — a new specialty retail customer that has entered our customer pipeline. Adjusted EBITDA came in slightly below last year.

Katarina Gabrielson

executive
#7

That came in at EUR 1.7 million. The cause behind that figure is the EUR 0.7 million one-off provision for product inventory I referred to earlier, which is hitting this segment in a negative way. Then, if we turn as well to what we discussed at the CMD, there too we discussed the way we engage with the customer, and likewise the way we handle the product portfolio. Within this segment, we have carried on aligning the product portfolio and have also brought the products into the sales channels that are growing. That is something we are now able to see in the results, particularly in sales. We will keep developing our own brands going forward, and we did so during the quarter as well. That covers the way we set prices for the product, the way we build the offering for customers, and strengthening competitiveness across the product groups relative to our other competitors. We keep seeing that the recent launches have been well received and are gaining new listings with our customers. Usually we speak a great deal about the major investments we make in Oriola. I will now use this opportunity to say a little about the continuous improvements we make, in fact, every day across our business.

Katarina Gabrielson

executive
#8

Today, we'll turn our attention somewhat to our supply chain operations and the efficiencies we achieve there. The supply chain, naturally, represents one of the largest expenses at Oriola, and it is absolutely vital that we pursue continuous improvement on a daily basis. As I noted earlier, our warehouses are also handling greater volumes, which naturally raises the capacity strain within those facilities. To balance these volumes, we make use of external warehousing. This is an area we actively work on in order to maximize net income and profitability, and also to manage new customers alongside rising stock levels. Beyond that, we devote considerable effort to transport, which stands among the major cost elements at Oriola. It is, of course, hugely important to work on route planning, delivery accuracy, and streamlining totes in the sorting processes, as well as examining route optimization. Here, we brought up route optimization in Northern Sweden. Looking at the map, you can see that Northern Sweden has relatively few inhabitants, yet there are many roads and long — many kilometers separating the various cities.

Katarina Gabrielson

executive
#9

This also gives us another way to bring transportation costs down. AI and digital tools are things we brought up and have discussed a great deal regarding the advisory business, but we also apply them in distribution and in our operations areas. So in supply chain, for instance, we're using digital tools and AI for inventory planning. That lets us have the right product, in the right volumes, at the right sites, so we can keep picking accuracy up for our customers, and it will also free up working capital on our balance sheet. With that, we then move to what we usually discuss, which is the strategic projects we're working on. At the CMD we said we should double the EBITDA by 2029 and strengthen the foundation for our future growth, and that this strategic project is a vital part of reaching that goal. During the quarter, we have now revised — updated the timeline for the ERP and warehouse management program. And I'll assure you here that this has not changed the fact that in 2029 we still have that goal of doubling the EBITDA.

Katarina Gabrielson

executive
#10

It's still in place. What we've now changed in the ERP and warehouse management program is that we've applied the lessons from the first deployment and, using those, put the strategy into practice with the new program — and also that we'll then have the Jarvenpaa distribution center at the end of this period. What we've done is reinforce the program and its governance. We're bringing more of it into our own business. So the internal organization has been made stronger and is taking greater ownership of the program as a whole. And we have also brought in — appointed a new implementation partner for this process. The revised timeline has been pushed out to 2029 — sorry, 2028 — so that it's also balanced with the Jarvenpaa distribution center, and it will involve a direct deployment into the Jarvenpaa distribution center. The investment has now also been revised, and we arrived at EUR 54 million, where before it was EUR 35 million. But this now makes possible the parallel core build in Sweden and in Finland, followed by what I mentioned earlier regarding this phased implementation. On top of this ERP and warehouse management program, of course, we're also carrying out some — within this scope, perhaps somewhat smaller projects, with the Enkoping automation upgrade.

Katarina Gabrielson

executive
#11

This matters a great deal for Sweden, since we can now see an opportunity in the first quarter of next year to move more volumes through Enkoping, and that is going to support growth in the business across both distribution and wholesale. I would also note here that the Jarvenpaa distribution center is continuing and moving forward according to the schedule. With that, I will now wrap up the business highlights and hand things over to Mats.

Mats Danielsson

executive
#12

Thanks, Katarina, and hello from me as well. Let's begin with the — to discuss our net sales. Net sales rose 5.1 percentage this quarter — that's the chart at middle top — and both the product segment and the Services segment drove it. In percentage terms, the product segment grew more, yet the Service segment in euros also delivered, with solid growth in both segments. Invoicing for the quarter came in at plus 3.4%. And looking at net sales year-to-date across the 3 quarters, we're at plus 1.6%. If we then strip out the Swedish dose dispensing business that we still had in quarter 1 in '25, growth comes to 4.1 percentage. Looking at the — so far this year, we've had a good — as Katarina said, we've seen good growth in the distribution segment, or the Services segment, the distribution part; we've had specialty flows such as exports and vaccines, and we've also had good sales of value-added services. And on the product side, there's been good development in the wholesale part, special-licensed medicines, and dose dispensing across all areas in the product segment has also been growing fairly well, particularly now in the third quarter.

Mats Danielsson

executive
#13

And for invoicing, year-to-date is up 5.6 percentage points. Now, when we turn to EBITDA, for the quarter we're at the same level as last year. That figure includes an inventory provision of minus EUR 0.7 million, which comes from the special-licensed medicines. It's a one-off booking we have, but we're still at the same level. Looking at the margin for the quarter, we're at 18.1% versus '19. If we adjusted the quarter for that provision, we would have come in at 19.4% versus 19%. So that's an improvement on that side. Looking at year-to-date, we're slightly above last year. Of course, that's now also affected by the provision. And as you may recall, we also faced higher freight costs because of fuel in the second quarter. At a high level, if we eliminate these 2 items, we show a margin percentage near 17% versus 16.1% last year. So we're also — the underlying EBITDA margin is expanding versus last year. Then moving into the Services segment, we've seen somewhat lower growth in invoicing from our customers.

Mats Danielsson

executive
#14

But net sales did get better, particularly during quarter 3. That ties closely to what was mentioned before. It's export vaccine and animal health that are growing. And on net sales we also have, naturally, the service fee from the value-added services we sell. Then during the quarter we also saw some expanded partnerships in Finland, which have helped support the growth. Advisory net sales remain below last year's level, which pulls the development down somewhat. Looking at adjusted EBITDA, we enjoyed a strong quarter, solid net sales growth, and EBITDA also improved, moving from EUR 9.6 million to EUR 10.1 million; year-to-date we trail last year, though we keep closing that gap. And naturally, in the Services segment especially, the quarter 2 fuel increase — the fuel prices — is weighing on the EBITDA figure. Moving on to the Product segment, it was a strong quarter across every area. We did well — let's say on the wholesale side, and the dose dispensing part performed well. Specialized medicines performed well too. So a genuinely strong development, plus 8.8 percentage. Year-to-date we sit at minus 3%, yet if we strip out the dose dispensing business in Sweden, net sales rose by 4.6 percentage.

Mats Danielsson

executive
#15

When we look at EBITDA, it's a bit below last year's figure. However, we've included the inventory provision here. And looking at year-to-date EBITDA, we're improving in spite of that provision we've had. And if we look at the EBITDA percentage margin, we're at -- excluding dose dispensing, we're at 9.8% versus 8.4%. And if we also take the provision out of the numbers, we're actually above 11% versus 8.4% last year. So an underlying improvement in the product segment. And if we look at year-to-date net profit, would take out one part here and look at the share of the result of krona, which is improving, of course, versus last year, which is a good thing for us. And we can also see that the profit for the period is actually EUR 8 million higher than last year. Then if we look at cash flow, 2 things here. We have the change in working capital. We have a reduced factoring that you see from the numbers also. We had EUR 122 million at the end of last year, and it's below EUR 100 million now.

Mats Danielsson

executive
#16

So it's over EUR 20 million that's hitting us — and that, naturally, is a onetime, one-off item, cutting back the factoring volumes with that customer. Then there's an invoicing mix change among customers during the autumn that has had an impact here as well. And on top of that, the product segment is expanding, which is also having a slight effect, and then we've got some FX differences. So a handful of significant factors are driving this. At the same time, we're aware that lowering the factoring will bring down our interest expenses. And even with interest rates higher, we've also managed to cut our interest expenses during the quarter. Investments came to EUR 8.5 million versus only EUR 1.8 million a year ago. The Jarvenpaa land area we've acquired is now included in this investment. And then the automation portion in Enkoping is likewise counted as an investment. So free cash flow is negative EUR 29.8 million against plus EUR 11.6 million last year. Looking at net debt, it sits pretty much at last year's level for the same period and is unchanged from quarter 2. Here we can also spot the large gap in sold receivables: EUR 99.6 million versus EUR 109 million last September, and it's also worth remembering that the figure was EUR 122 million at the close of last year.

Mats Danielsson

executive
#17

On the financial side, there are no major shifts in gearing or the equity ratio — we're at the same level as the prior quarter. Then we can move on and take a look at Kronans. I'd say what we're seeing now is the outcome of no longer working on the integration. You can tell the company is focused on the right priorities. There's a strong commercial emphasis — the pharmacies, opening hours, efficiencies within the pharmacies, campaigns, and how we can sell additional products. On the other side, an organizational restructuring has taken place, covering head office, but also the working hours in the pharmacies. When you look at adjusted EBIT, we're fairly close to last year's level. But when you look at EBIT for the quarter, well, there's a substantial gap. And that, of course, has an impact on the results for the period, and for the quarter as well. And particularly when we look at the same figures year-to-date, it's clear that integration costs were far higher last year than this year. So we have close to a EUR 5 million difference in the net result for the year-to-date, which, of course, has a major effect on our numbers too.

Mats Danielsson

executive
#18

And that was — the outlook still — yes, for the full year the outlook remains unchanged, and we're going to increase EBITDA from that EUR 35.1 million.

Katarina Gabrielson

executive
#19

Yes. And after that, I'll wrap up with the main takeaways. Looking at this, you could say net sales rose 5.1%, and net sales grew in both segments. We can see profitability has stayed resilient even with the one-off inventory you've heard so much about during this audio cast. We've also been able to pass the high fuel prices on to our customers. We can also see that customer partnerships have been extended, and new ones have been secured, which will be positive for the end of this year as well as next year. In wholesale, we're focusing on the growth channels and on the products that support profitable growth. We're also continuing with efficiency initiatives, both when it comes to bigger investments and how they are improving, and also the smaller ones we do every day. And this has generated savings and improved profitability -- productivity and profitability, of course. We are now building the foundation for growth. The ERP and VMS program and also the Jarvenpaa distribution center remain the key enablers for our modernization to reach the double profitability by 2029.

Katarina Gabrielson

executive
#20

As Mats mentioned a moment ago, we're reaffirming the guidance. Sales growth is anticipated to keep going in both segments, and strong commercial momentum that we're currently seeing in the market underpins that. Additionally, the new distribution partnerships we've established are positioned to make a positive contribution, and they already will contribute now in the fourth quarter. Actions on efficiency gains to offset increased fuel costs, along with continued cost discipline, support profitability — and that's among the reasons we are reiterating the outlook for the year. With that, I believe we'll wrap up the presentation.

Tua Stenius-Ornhjelm

executive
#21

Yes. Thank you. So thanks, Katarina and Mats, for walking us through the quarter. And we'll now move on to your questions. And you can keep submitting them via the chat. And as a reminder, we'll start with questions concerning Oriola's business and financial performance. And we already have quite a few questions, and I'll do my best to group them by topic. And there are a lot of questions concerning the ERP. So I'll take those first and then go on with the other ones. So will the new ERP and WMS be live before Jarvenpaa begins operations in Q1 2028? And if not, will you postpone the move or open Jarvenpaa on the current system?

Katarina Gabrielson

executive
#22

You could put it that way — as I mentioned, this implementation will happen in phases. In Sweden, the plan is to go ahead of Finland. So in that sense, yes, it will be live before we get to Jarvenpaa, but the plan here is to take the new system straight into Jarvenpaa when we go in Finland.

Tua Stenius-Ornhjelm

executive
#23

Okay. And out of that approximately EUR 29 million in ERP costs that are still ahead, what portion is going to hit in 2027?

Mats Danielsson

executive
#24

This year we'll still recognize roughly EUR 5 million. So the total for this year comes to EUR 15 million. Next year it should land at about EUR 15 million, and after that, the remainder will be slightly under EUR 10 million, at the latest in '28.

Tua Stenius-Ornhjelm

executive
#25

And then I have a follow-up question. So could you lay out what possibilities ERP will now have when it comes to business efficiency and the competitiveness of Oriola, compared with what would have been the case if Oriola had carried on according to the first deployment in Sweden?

Katarina Gabrielson

executive
#26

I'd put it this way: from an efficiency standpoint, that isn't what we've altered in the program. The program is designed to examine processes, how we work, and so forth. That remains the same portion of the scope. What we've changed at this point is the way we carry out the implementation, how we structure the program so as to remove risks from the overall program element and then also be able to launch it in the phases where we believe. That's what's best for the company. And as I said earlier, the platform and this piece are crucial for the business going forward, and it's also very important for the overall business plan and strategy we have from 2028 onwards and the '29 results.

Tua Stenius-Ornhjelm

executive
#27

All right. And then could you say whether Oriola will seek compensation from HCL Tech over the ERP project? If that compensation does come in, would it be treated as an adjusting item? Just to note, this is the partner we had previously.

Katarina Gabrielson

executive
#28

On the implementation partner — yes. We haven’t discussed the contracts or exactly how we’ll handle that. And of course, if anything comes up, you’ll see it reflected in the numbers.

Tua Stenius-Ornhjelm

executive
#29

All right, so those were the questions tied to the ERP program at that moment. Let's move on now to the remaining questions. First, regarding the Services segment: Services EBITDA increased once more even though advisory is still soft. How should we view the margin path from here going forward?

Mats Danielsson

executive
#30

Right, we saw solid growth in quarter 3, and we expect that to keep building so we hit the full year numbers. That segment needs both growth and profitability.

Katarina Gabrielson

executive
#31

What we're also seeing in the Service segment is that, as we mentioned here, we now have more customers. We onboarded customers during quarter 3, and that's going to have a positive effect on quarter 4. We've also been working on profitability with each customer. So that plays into the guidance, of course, but it's also something we can see in this segment.

Tua Stenius-Ornhjelm

executive
#32

Okay, so moving on to a question about the product segment. What was behind the clear EBITDA improvement in products at the underlying level? And how repeatable is that?

Katarina Gabrielson

executive
#33

I'd say it is repeatable, because when you look at this, a lot of it comes down to growth. Net sales growth in the main part of the businesses is what we have, and that has positively affected adjusted EBITDA. And what we've done now — as I said here — is to work with the basic part in this segment. So as we work with the products, we get new launches and so on, and that will also affect the earnings going forward.

Tua Stenius-Ornhjelm

executive
#34

All right, good. Then a few questions about the remainder of the year. So Q4 and guidance. Could you take us through the main building blocks? What are the ways you'll get better in Q4?

Katarina Gabrielson

executive
#35

Naturally, we'll keep going with the net sales growth, and also the profitable growth, that we delivered in quarter 3, and then build further on that. We can see as well that the new distribution partnerships we just referred to will keep — will already make a positive contribution in the fourth quarter. So that's one piece. And then we're doing a great deal on costs and efficiency gains, to offset the elevated fuel costs, both through the continuous improvements we mentioned earlier here, but also through the everyday cost control that we have across the board. So there are many small items, but carry on with what we did in quarter 3 and improve on it.

Tua Stenius-Ornhjelm

executive
#36

Thanks. Now on the topic of fuel prices — they've gone up once more this fall. Should we be anticipating a negative effect on Q4 because of that, the way we saw in Q2?

Katarina Gabrielson

executive
#37

What I'd say is that at this point we've got the contracts in place. And I don't expect quarter 4 to take a negative hit the way we saw in quarter 2. We've already worked on that in quarter 3, and it ought to stay as it is in quarter 4.

Tua Stenius-Ornhjelm

executive
#38

All right, good. Those were every one of the questions about Oriola. So at this point we'll turn to questions regarding Kronans Apotek. Just a quick reminder to please send in your questions via the chat. There's invariably a bit of a lag before they reach us, which lets us pick them up during the audio cast. So the first question now: Kronans has had a new Chairman in place for 2 months. Could you share his views regarding the plus EUR 60 million EBITDA target for Kronans by 2029 that was presented at the CMD? In his assessment, is this achievable? Or should we anticipate that this target will be revised?

Katarina Gabrielson

executive
#39

Clearly, I'm not Magnus Hakansson, and naturally, he would usually address this point on his own. Still, I'm aware that he, along with the entire Board — management included — remains dedicated to what we laid out at the CMD. Nothing has shifted on that front, despite the fact that we've made a few adjustments to how the Board is composed. So the targets, as well as the actions and goals we set out at the CMD, remain entirely in force.

Tua Stenius-Ornhjelm

executive
#40

Great. And then at the CMD, Oriola laid out a savings goal of EUR 20 million for Kronans by 2027. Could you say how much of that had been reached by Q3? And how much should we expect to show up in Q4?

Mats Danielsson

executive
#41

A portion of it, of course, as you can see in the figures, is in the quarter now. Quarter 4 will include more, and the remainder of the program will show up next year. So the program is working.

Tua Stenius-Ornhjelm

executive
#42

Good. Now, the last question. It ties somewhat to what you just mentioned, Mats, though perhaps we can broaden it a bit. So Kronans has gotten better in Q2 and Q3. Are those efficiency measures that were presented at the CMD paying off?

Mats Danielsson

executive
#43

They are functioning well. They are functioning across every area we outlined, including personnel costs as well; the work on pharmacies and the various activities they run around pharmacy sales is functioning. And they are concentrating, and they — once the integration is finished, they have the time and energy to focus on that rather than on integrating the 2 companies and the systems.

Katarina Gabrielson

executive
#44

At a high level...

Mats Danielsson

executive
#45

When it comes to the fundamentals of retail, we're making enhancements.

Tua Stenius-Ornhjelm

executive
#46

Alright. Thanks. That appears to be every question we had for today. So, thanks to all of you for being with us today. Should there be anything more you'd like to talk over with us, please don't hesitate to reach out afterward. Thanks once more, and enjoy the remainder of your week.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Oriola Oyj transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Oriola Oyj earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Oriola Oyj or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.